158
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Cost-of-illness studies of atrial fibrillation: methodological considerations

References

  • Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112(8):1142-7
  • Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013;34(35):2746-51
  • Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012;142(6):1489-98
  • Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129(8):837-47
  • Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15(4):486-93
  • Heeringa J, Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27(8):949-53
  • Leong DP, Eikelboom JW, Healey JS, Connolly SJ. Atrial fibrillation is associated with increased mortality: causation or association? Eur Heart J 2013;34(14):1027-30
  • Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991;22(8):983-8
  • Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med 2012;172(9):739-41
  • Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study. Circulation 2004;110(9):1042-6
  • Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmcoeconomics 2011;29(8):653-71
  • Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies : a review of current methods. Pharmacoeconomics 2006;24(9):869-90
  • Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 2008;11(1):13-21
  • Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77(1):51-63
  • Molinier L, Bauvin E, Combescure C, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 2008;11(5):878-85
  • Drummond M, Drummond M. Methods for the economic evaluation of health care programmes. Oxford University Press; Oxford, New York, NY, USA: 2005
  • Ó Céilleachair A, Hanly P, Skally M, et al. Cost comparisons and methodological heterogeneity in cost-of-illness studies: the example of colorectal cancer. Med Care 2013;51(4):339-50
  • O’Reilly DJ, Hopkins RB, Healey JS, et al. The burden of atrial fibrillation on the hospital sector in Canada. Can J Cardiol 2013;29(2):229-35
  • Keech M, Punekar YS, Choy AM. Trends in atrial fibrillation hospitalisation in Scotland: an increasing cost burden. Br J Cardiol 2012;19(4):173-7
  • Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90(3):286-92
  • Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9(5):348-56
  • Ericson L, Bergfeldt L, Björholt I. Atrial fibrillation: the cost of illness in Sweden. Eur J Health Econ 2011;12(5):479-87
  • Amin AN, Jhaveri M, Lin J. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther 2011;28(10):907-26
  • Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ 2008;11(2):281-98
  • Pelletier E, Hernandez J, Clark M, et al. Medicare costs and health resource utilisation associated with atrial fibrillation in the elderly. J Med Econom 2005;8(1-4):55-65
  • Reinhold T, Lindig C, Willich SN, Bruggenjurgen B. The costs of atrial fibrillation in patients with cardiovascular comorbidities – a longitudinal analysis of German health insurance data. Europace 2011;13(9):1275-80
  • Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4(3):313-20
  • Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21(10):1693-9
  • Rohrbacker NJ, Kleinman NL, White SA, et al. The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: associated costs, absences, and objective productivity loss. J Occup Environ Med 2010;52(4):383-91
  • Boccuzzi SJ, Martin J, Stephenson J, et al. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Curr Med Res Opin 2009;25(12):2853-64
  • Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26(9):847-57
  • Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy 2009;29(12):1417-26
  • Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc 2013;2(6):e000479
  • Bhave PD, Goldman LE, Vittinghoff E, et al. Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery. Am Heart J 2012;164(6):918-24
  • Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol 2007;18(6):628-33
  • Ghatnekar O, Glader EL. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health 2008;11(5):862-8
  • Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004;147(1):121-6
  • McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 2009;12(2):293-301
  • Reinhold T, Rosenfeld S, Muller-Riemenschneider F, et al. [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs]. Herz 2012;37(5):534-42
  • Jönsson L, Eliasson A, Kindblom J, et al. Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany. Appl Health Econ Health Policy 2010;8(5):317-25
  • Scheuringer M, Sahakyan N, Krobot KJ, Ulrich V. Cost of clinical events in health economic evaluations in Germany: a systematic review. Cost Eff Resour Alloc 2012;10(1):7
  • Brüggenjürgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007;10(2):137-43
  • Rostagno C, La Meir M, Gelsomino S, et al. Atrial fibrillation after cardiac surgery: incidence, risk factors, and economic burden. J Cardiothorac Vasc Anesth 2010;24(6):952-8
  • Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 2008;10(4):403-11
  • Holstenson E, Ringborg A, Lindgren P, et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. Europace 2011;13(1):23-30
  • Bruggenjurgen B, Reinhold T, McBride D, Willich SN. [Atrial fibrillation--epidemiologic, economic and individual burden of disease]. Dtsch Med Wochenschr 2010;135(Suppl 2):S21-5
  • Kassianos G, Arden C, Hogan S, et al. The non-anticoagulation costs of atrial fibrillation management: findings from an observational study in NHS Primary Care. Drugs Context 2014;2014:212254
  • Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000;320(7245):1335
  • Murin J, Naditch-Brule L, Brette S, et al. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One 2014;9(1):e86443
  • Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. Value Health 2007;10(5):336-47
  • Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law 2008;33(2):225-47
  • Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ. A cross-national perspective on cost of illness: a comparison of studies from The Netherlands, Australia, Canada, Germany, United Kingdom, and Sweden. Eur J Health Econ 2005;6(3):223-32
  • Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22(13):857-76
  • Danzon PM, Wilensky GR, Means KE. Alternative strategies for Medicare payment of outpatient prescription drugs – Part B and beyond. Am J Manag Care 2005;11(3):173-80
  • Krauth C, Hessel F, Hansmeier T, et al. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation - ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen 2005;67(10):736-46
  • Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20(7):443-54
  • Costa N, Derumeaux H, Rapp T, et al. Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2012;2(1):18
  • Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health 2012;15(2):240-8
  • Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13(10):1375-85
  • Larsen TB, Lip GY. Warfarin or novel oral anticoagulants for atrial fibrillation? Lancet 2014;383(9921):931-3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.